Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
Published:
Last Updated:
Celgene is scheduled to report its third-quarter financial results before the markets open on Thursday.
Published:
Last Updated:
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
Published:
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
Published:
These three top biotech names are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Published:
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
Published:
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Published:
A new report from Cowen points out that many skittish portfolio managers are anxiously awaiting third-quarter numbers to make sure that the biotech thesis is still in place.
Published:
Thursday's top analyst upgrades, downgrades and initiations include AGCO, Celgene, Devon Energy, JD.com, Microsoft, SanDisk, Crocs and Illumina.
Published:
Jefferies is basically positive overall going into earnings, and many on Wall Street are projecting a solid fourth-quarter run for the markets.
Published:
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.
Published:
In a recent research report, Jefferies highlighted three top biotech companies that are very tempting buys now.
Published:
The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Published:
While Jefferies thinks the Fed waits until December to raise rates, there is always a chance it will happen this week.
Published:
In a new and very comprehensive report, Jefferies starts coverage on biotechs with some very targeted stock selections.
Published: